W G Kunz1, C J Auernhammer2, S Nölting2, T Pfluger3, J Ricke4, C C Cyran4. 1. Klinik und Poliklinik für Radiologie, Klinikum der Universität München, Marchioninistr. 15, 81377, München, Deutschland. wolfgang.kunz@med.lmu.de. 2. Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Deutschland. 3. Klinik und Poliklinik für Nuklearmedizin, Klinikum der Universität München, München, Deutschland. 4. Klinik und Poliklinik für Radiologie, Klinikum der Universität München, Marchioninistr. 15, 81377, München, Deutschland.
Abstract
CLINICAL BACKGROUND: If pheochromocytoma (PC) or paraganglioma (PGL) is diagnosed based on serologic studies, imaging is required to locate the adrenal mass for further management. Besides pathognomonic hormonal findings, PC/PGL can exhibit typical imaging features. However, PC/PGL can also show morphological overlap with other pathologies. STANDARD RADIOLOGICAL METHODS: The modality of choice for evaluation of PC is CT. In case of extra-adrenal location, MRI is superior to CT. Imaging with PET-CT provides complementary information in the differentiation of PC/PGL and is recommended as the imaging modality of choice for malignant PC/PGL. 68Ga-DOTATATE (or 68Ga-DOTATOC/ 68Ga-DOTANOC) PET-CT has high sensitivity for SDHx-mutated PC/PGL and serves for planning of radioreceptor therapy with somatostatin analogues. In contrast, 123I-metaiodobenzylguanidine (MIBG) scintigraphy is important in assessing the potential efficacy of radioreceptor therapy with MIBG. METHODICAL DETAILS: The CT protocol for PC evaluation should include non-enhanced, arterial, portal-venous and late phases; the latter for the evaluation of wash-out. Recent studies indicate non-enhanced CT alone may be sufficient to rule out PC. For MRI, in- and opposed-phase sequences should be additionally acquired. PRACTICAL RECOMMENDATIONS: A relevant proportion of PC is diagnosed incidentally. Therefore, imaging of PC will gain further importance. Recent studies show better response rates of PC/PGL after radioreceptor therapy with somatostatin analogues (177Lu-DOTATATE) than with MIBG. Therefore, 68Ga-DOTATATE PET-CT gains further importance-for diagnostic imaging and therapy planning.
CLINICAL BACKGROUND: If pheochromocytoma (PC) or paraganglioma (PGL) is diagnosed based on serologic studies, imaging is required to locate the adrenal mass for further management. Besides pathognomonic hormonal findings, PC/PGL can exhibit typical imaging features. However, PC/PGL can also show morphological overlap with other pathologies. STANDARD RADIOLOGICAL METHODS: The modality of choice for evaluation of PC is CT. In case of extra-adrenal location, MRI is superior to CT. Imaging with PET-CT provides complementary information in the differentiation of PC/PGL and is recommended as the imaging modality of choice for malignant PC/PGL. 68Ga-DOTATATE (or 68Ga-DOTATOC/ 68Ga-DOTANOC) PET-CT has high sensitivity for SDHx-mutated PC/PGL and serves for planning of radioreceptor therapy with somatostatin analogues. In contrast, 123I-metaiodobenzylguanidine (MIBG) scintigraphy is important in assessing the potential efficacy of radioreceptor therapy with MIBG. METHODICAL DETAILS: The CT protocol for PC evaluation should include non-enhanced, arterial, portal-venous and late phases; the latter for the evaluation of wash-out. Recent studies indicate non-enhanced CT alone may be sufficient to rule out PC. For MRI, in- and opposed-phase sequences should be additionally acquired. PRACTICAL RECOMMENDATIONS: A relevant proportion of PC is diagnosed incidentally. Therefore, imaging of PC will gain further importance. Recent studies show better response rates of PC/PGL after radioreceptor therapy with somatostatin analogues (177Lu-DOTATATE) than with MIBG. Therefore, 68Ga-DOTATATE PET-CT gains further importance-for diagnostic imaging and therapy planning.
Authors: Ingo Janssen; Elise M Blanchet; Karen Adams; Clara C Chen; Corina M Millo; Peter Herscovitch; David Taieb; Electron Kebebew; Hendrik Lehnert; Antonio T Fojo; Karel Pacak Journal: Clin Cancer Res Date: 2015-04-14 Impact factor: 12.531
Authors: K Lorenz; P Langer; B Niederle; P Alesina; K Holzer; Ch Nies; Th Musholt; P E Goretzki; N Rayes; M Quinkler; J Waldmann; D Simon; A Trupka; R Ladurner; K Hallfeldt; A Zielke; D Saeger; Th Pöppel; G Kukuk; A Hötker; P Schabram; S Schopf; C Dotzenrath; P Riss; Th Steinmüller; I Kopp; C Vorländer; M K Walz; D K Bartsch Journal: Langenbecks Arch Surg Date: 2019-04-01 Impact factor: 3.445
Authors: Benjamin G Northcutt; Siva P Raman; Christopher Long; Alexander R Oshmyansky; Stanley S Siegelman; Elliot K Fishman; Pamela T Johnson Journal: AJR Am J Roentgenol Date: 2013-10 Impact factor: 3.959
Authors: B Lechner; D Heinrich; S Nölting; A Osswald-Kopp; G Rubinstein; J Sauerbeck; F Beuschlein; M Reincke Journal: Internist (Berl) Date: 2018-11 Impact factor: 0.743
Authors: Aurélien Archier; Arthur Varoquaux; Philippe Garrigue; Marion Montava; Carole Guerin; Sophie Gabriel; Eva Beschmout; Isabelle Morange; Nicolas Fakhry; Frédéric Castinetti; Frédéric Sebag; Anne Barlier; Anderson Loundou; Benjamin Guillet; Karel Pacak; David Taïeb Journal: Eur J Nucl Med Mol Imaging Date: 2015-12-05 Impact factor: 9.236
Authors: P F Plouin; L Amar; O M Dekkers; M Fassnacht; A P Gimenez-Roqueplo; J W M Lenders; C Lussey-Lepoutre; O Steichen Journal: Eur J Endocrinol Date: 2016-05 Impact factor: 6.664
Authors: Natalie Rogowski-Lehmann; Aikaterini Geroula; Aleksander Prejbisz; Henri J L M Timmers; Felix Megerle; Mercedes Robledo; Martin Fassnacht; Stephanie Fliedner; Martin Reincke; Anthony Stell; Andrzej Januszewicz; Jacques Lenders; Graeme Eisenhofer; Felix Beuschlein Journal: Endocr Connect Date: 2018-09-01 Impact factor: 3.335